A new study from the University of Chicago has investigated whether neural complexity is increased after low doses of LSD, and moderate to high doses of...
The high of MDMA (a.k.a.
Mind Medicine has presented positive topline data in Basel, Switzerland in April from a double-blind, investigator-initiated trial evaluating lysergide (LSD) in the treatment of Major Depressive...
In 1943, Swiss chemist Albert Hofmann took the first LSD trip.
A team of scientists has developed LSD-like compounds that fit into the 5HT2a receptor – the main target of substances such as LSD and psilocybin.
Data from a collaborative study between the University Hospital Basel (UHB) and MindMed supports the clinical development of MindMed’s proprietary MM-120 product candidate – a pharmacologically...
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
Freedom to Operate has published its new study that can be used to fight back against anyone attempting to patent a polymorphic form of LSD and...
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...
